Cargando…

Immunotherapy Strategies Against Multiple Myeloma

Multiple myeloma is a monoclonal B-cell malignancy characterized by an accumulation of malignant plasma cells in the bone marrow, the presence of a monoclonal protein in the serum and/or urine, decreased normal immunoglobulin levels, and lytic bone disease. Patients with multiple myeloma benefit fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Jing, Li, Qian, Yu, Zhen, Cao, Zeng, Liu, Su, Chen, Lin, Li, Han, Gao, Shuang, Yan, Tinghui, Wang, Yafei, Liu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762093/ http://dx.doi.org/10.1177/1533034617743155

Ejemplares similares

Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor in Multiple Myeloma
por: Wang, Yafei, et al.
Publicado: (2022)

Correlation Between Uptake of (18)F-FDG During PET/CT and Ki-67 Expression in Patients Newly Diagnosed With Multiple Myeloma Having Extramedullary Involvement
por: Li, Qian, et al.
Publicado: (2019)

Multiple myeloma with dural mater involvement
por: Liu, Su, et al.
Publicado: (2019)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients
por: Li, Qian, et al.
Publicado: (2020)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Cellular immunotherapy using dendritic cells against multiple myeloma
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

The Role of Immunotherapy in Multiple Myeloma
por: Kocoglu, Mehmet, et al.
Publicado: (2016)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

Immunotherapy for the treatment of multiple myeloma
por: Boussi, Leora S., et al.
Publicado: (2022)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
por: Danylesko, Ivetta, et al.
Publicado: (2012)

Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma
por: Li, Rong, et al.
Publicado: (2020)

Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma
por: Reina-Ortiz, Chantal, et al.
Publicado: (2022)

Development of Novel Immunotherapies for Multiple Myeloma
por: Al-Hujaily, Ensaf M., et al.
Publicado: (2016)

Is immunotherapy here to stay in multiple myeloma?
por: Rodríguez-Otero, Paula, et al.
Publicado: (2017)

Immunotherapy of Multiple Myeloma: Promise and Challenges
por: Abramson, Hanley N
Publicado: (2021)

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
por: Ma, Tiantian, et al.
Publicado: (2019)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)

Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma
por: Zhang, Lu, et al.
Publicado: (2012)

Cell-based immunotherapy approaches for multiple myeloma
por: Kriegsmann, Katharina, et al.
Publicado: (2018)

Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
por: Serrano-del Valle, Alfonso, et al.
Publicado: (2019)

Novel immunotherapies in multiple myeloma – chances and challenges
por: Rasche, Leo, et al.
Publicado: (2021)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Talquetamab: A promising immunotherapy for multiple myeloma
por: Tariq, Amna, et al.
Publicado: (2023)

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
por: Hoang, My-Dung, et al.
Publicado: (2015)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
por: Shah, Nina, et al.
Publicado: (2020)

Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells
por: Li, Qian, et al.
Publicado: (2018)

Understanding the Mechanisms of Resistance to T Cell-based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma
por: Ahn, Sungwoo, et al.
Publicado: (2021)

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2017)

Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2015)

Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2019)

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
por: Bobin, Arthur, et al.
Publicado: (2020)

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
por: Abramson, Hanley N.
Publicado: (2023)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ik2t9892jh3m16qhjjv8de5r2c